 Plus Therapeutics Inc NASDAQ: PSTV has announced that the first patient in the eighth cohort of Phase 1 dose-escalation ReSPECT-GBM trial for recurrent glioblastoma rGBM has been treated. The present cohort implements a 40 increase in volume 12.3 milliliters and total radioactivity 31.2 millicuries from the previous cohort. 